NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.
November 9, 2025 — Study finds cash rewards doubled blood pressure medication adherence but didn't improve blood pressure outcomes. Research reveals complex relationship between medication-taking behavior and health results.
November 9, 2025 — American Heart Association launches Heart Valve Initiative with Edwards Lifesciences to combat rising heart valve disease affecting 28M globally. New program aims for earlier diagnosis & better treatment.
November 9, 2025 — New study shows personalized vitamin D dosing reduces heart attack risk by 52% in adults with heart disease. Research presented at American Heart Association Scientific Sessions 2025.
November 9, 2025 — Groundbreaking study reveals daily coffee consumption reduces atrial fibrillation recurrence by 39% in AFib patients, challenging conventional medical wisdom about caffeine and heart health.
November 8, 2025 — New study shows earlier blood transfusions reduce heart failure risk by 41% in cardiac surgery patients. Research challenges traditional transfusion timing guidelines for better outcomes.
November 8, 2025 — Groundbreaking study finds catheter ablation for atrial fibrillation may eliminate need for blood thinners, reducing stroke risk without increased bleeding complications in moderate-risk patients.
November 8, 2025 — New research shows standard medical care outperforms left atrial appendage closure for high-risk atrial fibrillation patients in preventing stroke and bleeding complications.
November 8, 2025 — New study shows 1-month clot prevention after stent placement in AFib patients is as effective as year-long therapy with 50% fewer bleeding complications.
November 8, 2025 — New daily oral medication enlicitide reduces LDL cholesterol by 60%, matching injectable PCSK9 inhibitors. Study presented at American Heart Association Scientific Sessions 2025 shows promise for high-risk patients.
November 8, 2025 — VESALIUS-CV trial shows evolocumab reduces first major cardiovascular events by 25% in high-risk patients without prior heart attack or stroke. Breakthrough PCSK9 inhibitor findings.
November 8, 2025 — CRISPR gene therapy CTX310 reduces LDL cholesterol by 50% and triglycerides by 55% in single treatment. Phase 1 trial shows sustained results for 60+ days in patients with lipid disorders.
November 8, 2025 — New medication DR10624 reduces triglycerides over 60% and cuts liver fat by 63% in clinical trial. First drug targeting FGF21, glucagon & GLP-1 receptors simultaneously for severe hypertriglyceridemia.
November 8, 2025 — Fifth Annual Sickle Cell Caregiver Summit offers virtual support Nov 13-16, 2025. Join global community for mental wellness, advocacy training & caregiver resources.
November 7, 2025 — Voyageur Pharmaceuticals appoints Virginia Alling to board, strengthening leadership for US market expansion of pharmaceutical-grade barium and iodine contrast media products.
November 7, 2025 — Sapu Nano, an Oncotelic venture, receives HREC approval for Sapu003 breast cancer trials using innovative Deciparticle technology for intravenous everolimus delivery.
November 7, 2025 — Olympus unveils strategy to transform endoscopy care using AI, robotics & digital ecosystems. Includes workforce changes, financial targets & leadership transitions for global MedTech innovation.
November 7, 2025 — Knecht Orthodontics in Mont Belvieu offers braces & Invisalign with advanced technology & personalized care. Find your ideal orthodontist near me for beautiful smiles.
November 7, 2025 — Soligenix reports Q3 2025 results with key milestones for HyBryte™ in CTCL and SGX302 in psoriasis. Company maintains strong cash position and advances rare disease treatments.
November 7, 2025 — New study reveals immune cells shed surface sugars before entering psoriatic skin, opening new treatment pathways. Research could transform psoriasis care for millions worldwide.
November 6, 2025 — Soligenix advances SGX302 phase 2a trial for psoriasis treatment, building on promising data in the $67B dermatology market. Company expands hypericin therapy pipeline.